Assertio Therapeutics is committed to providing responsible solutions to advance patient care in the Companyâs core areas of neurology, orphan and specialty medicines. Assertio currently markets three FDA-approved products and continues to identify, license and develop new products that offer enhanced options for patients that may be underserved by existing therapies. Source
No articles found.
As of June 30, 2019, Sabraâs investment portfolio included 432 real estate prope...
As of June 30, 2019, Sabraâs investment portf...
Neurotrope is a clinical-stage biotech company leveraging Bryostatin-1 and its ana...
Neurotrope is a clinical-stage biotech company ...
PDL BioPharma (NASDAQ: PDLI) seeks to provide a significant return for its shareho...
PDL BioPharma (NASDAQ: PDLI) seeks to provide a...
Onconova Therapeutics, Inc. is a Phase 3-stage biopharmaceutical company focused o...
Onconova Therapeutics, Inc. is a Phase 3-stage ...
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, dev...
Cytokinetics is a late-stage biopharmaceutical ...
Dova is a pharmaceutical company focused on acquiring, developing and commercializ...
Dova is a pharmaceutical company focused on acq...
Acorda Therapeutics is a biotechnology company focused on developing therapies tha...
Acorda Therapeutics is a biotechnology company ...
Join the National Investor Network and get the latest information with your interests in mind.